LIGHTHOUSE Trial and The Role of 18F-rhPSMA-7.3 for Staging of Prostate Cancer

Dr. Chapin and fellow expert oncologists discuss the latest data from the LIGHTHOUSE trial, evaluating 18F-rhPSMA-7.3 for staging patients with prostate cancer.

EP: 1.The Evolution of Imaging Techniques in Prostate Cancer

EP: 2.The Utility of PSMA PET in Prostate Cancer

EP: 3.Clinical Development of PSMA-Targeted Therapies

EP: 4.Clinical Practices of PSMA-Targeted Agents in Prostate Cancer

EP: 5.Multidisciplinary Approaches in PSMA PET for Prostate Cancer

EP: 6.Patient Profile 1: A 51-Year-Old Man with High-Risk Localized Prostate Cancer

EP: 7.PSMA PET Imaging and Clinical Perspectives from Patient Profile 1

Now Viewing

EP: 8.LIGHTHOUSE Trial and The Role of 18F-rhPSMA-7.3 for Staging of Prostate Cancer

EP: 9.An Overview of the SPOTLIGHT Trial for PSMA PET in Prostate Cancer

EP: 10.SPOTLIGHT Trial and 18F-rhPSMA-7.3 for Prostate Cancer

EP: 11.Patient Profile 2: A 62-Year-Old Man with Recurrent Prostate Cancer

EP: 12.Patient Profile 3: A 67-Year-Old Male with Recurrent Prostate Cancer

EP: 13.Future Horizons in PSMA-Targeted Imaging and the Management of Prostate Cancer

Related Videos

Related Content

Advertisement

April 25th 2025

FDA clears AI-powered application for measuring prostate volume

Benjamin P. Saylor

Clarius Mobile Health said it will be demonstrating the application at the AUA Annual Meeting in Las Vegas, Nevada.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

April 21st 2025

AUA 2025: What to watch for in urologic oncology

Benjamin P. Saylor Hannah Clarke

We preview several noteworthy P2 presentations in the urologic oncology space.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

April 15th 2025

Dose expansion begins in phase 1/2 trial of 67Cu-SAR-bisPSMA in mCRPC

Hannah Clarke

The first patient in the trial will be receiving 67Cu-SAR-bisPSMA in combination with enzalutamide.

April 14th 2025

Study underway to assess 3-fraction SBRT regimen in prostate cancer

Hannah Clarke

"The goal of the PRECISION study is to ensure that treatment with 3 radiation doses does not lead to greater side effects than those observed in the PACE-B study," says Professor Duncan B. McLaren, MBBS.

Related Content

Advertisement

April 25th 2025

FDA clears AI-powered application for measuring prostate volume

Benjamin P. Saylor

Clarius Mobile Health said it will be demonstrating the application at the AUA Annual Meeting in Las Vegas, Nevada.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

April 21st 2025

AUA 2025: What to watch for in urologic oncology

Benjamin P. Saylor Hannah Clarke

We preview several noteworthy P2 presentations in the urologic oncology space.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

April 15th 2025

Dose expansion begins in phase 1/2 trial of 67Cu-SAR-bisPSMA in mCRPC

Hannah Clarke

The first patient in the trial will be receiving 67Cu-SAR-bisPSMA in combination with enzalutamide.

April 14th 2025

Study underway to assess 3-fraction SBRT regimen in prostate cancer

Hannah Clarke

"The goal of the PRECISION study is to ensure that treatment with 3 radiation doses does not lead to greater side effects than those observed in the PACE-B study," says Professor Duncan B. McLaren, MBBS.